相关临床试验
1489
255 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1963
终止
51
3.4%
招募中
374
25.1%
暂停
2
0.1%
撤回
30
2.0%
进行中（未招募）
91
6.1%
Unknown
185
12.4%
已完成
592
39.8%
Enrolling By Invitation
15
1.0%
尚未招募
149
10.0%
暂无批准数据
- New research in mice overturns the long-held belief that collateral arteries arise from pre-existing arteries, showing instead that capillaries are the primary building blocks of new coronary collaterals. - A CUHK–CAS joint team used a novel genetic lineage-tracing "cell-contact history recorder" to track endothelial cell origins during collateral artery formation after coronary blockage. - The study identifies a VEGFA–YY1 signaling axis as the master driver of capillary-to-artery conversion, with transient mRNA-based VEGFA delivery improving heart function in injured mice. - The findings, published in Science, point to a tractable therapeutic target for ischaemic heart disease, the leading cause of death worldwide.
- A surgical procedure for Alzheimer's disease pioneered in Hangzhou in 2018 is now under controlled clinical investigation at CUHK following a national ban on its unregulated use in July 2025. - CUHK researchers have obtained regulatory approval and recruited four patients, with one described by his wife as a "completely new person… so sharp" after recovery. - China's National Health Commission banned the procedure's unregulated application due to safety and effectiveness concerns, pledging to review it once sufficient evidence becomes available. - Dr. Tor Chiu of CUHK stated the research team aims to verify whether the procedure, performed under strict scientific controls, can improve Alzheimer's patients' condition.
- Researchers at The Chinese University of Hong Kong conducted the world's first randomized clinical trial evaluating GLP-1 receptor agonists in severe stroke patients undergoing reperfusion therapy. - The Phase 2 trial involving 140 patients demonstrated that semaglutide is safe and well-tolerated in acute stroke settings with no severe adverse events attributed to the drug. - Exploratory analyses revealed a potential 20% improvement in neurological recovery among patients who did not receive intravenous thrombolysis before thrombectomy. - The findings provide early clinical evidence supporting the safety of GLP-1RAs in stroke treatment and pave the way for larger Phase 3 trials to confirm neuroprotective potential.
- Hua Medicine's dorzagliatin (MYHOMSIS®) becomes the first glucokinase activator approved outside mainland China, securing marketing authorization in Hong Kong for Type 2 diabetes treatment. - The global first-in-class drug targets glucokinase to restore glucose homeostasis through multi-organ action on pancreatic β-cells, intestinal L-cells, and liver metabolism. - Hong Kong approval leverages the "1+" regulatory mechanism and positions the company for Southeast Asian market expansion, with over 200,000 patients already treated in mainland China. - The drug offers differentiated therapy options as monotherapy for drug-naïve patients or combination treatment with metformin for inadequate glucose control cases.
- The phase 3 KEYNOTE-937 trial demonstrated that adjuvant pembrolizumab failed to improve recurrence-free survival compared to placebo in hepatocellular carcinoma patients who achieved complete radiological response after surgical resection or local ablation. - Median recurrence-free survival was nearly identical between treatment arms at 46.7 months for pembrolizumab versus 45.5 months for placebo, with no statistical significance. - The study enrolled 959 patients and found no benefit in overall survival or distant metastasis-free survival, while pembrolizumab was associated with higher rates of grade 3-4 treatment-related adverse events. - These negative results indicate that adjuvant PD-1 inhibition does not provide clinical benefit in the curative-intent hepatocellular carcinoma setting.
- The Chinese University of Hong Kong and spin-off MicroSigX have launched the world's first AI-powered multikingdom microbial biomarkers technology for autism spectrum disorder risk detection in children. - The non-invasive test analyzes gut microbiome samples to generate ASD risk scores with over 95% negative predictive value, helping exclude low-risk cases and reduce parental anxiety. - The technology received FDA Breakthrough Device Designation in July 2024 and will offer 200 free tests to eligible preschool children starting January 2026. - CU Medicine will establish an "Advancement Centre for Autism" to develop training programs and create a holistic care network for comprehensive ASD support.
- The Hong Kong Department of Health has accepted Hua Medicine's New Drug Application for dorzagliatin, the world's first approved glucokinase activator for Type 2 diabetes treatment. - Dorzagliatin targets the root cause of blood sugar dysregulation by repairing glucokinase function, demonstrating sustained HbA1c reduction and improved pancreatic β-cell function in Phase III trials. - The approval marks a strategic milestone for Hua Medicine's international expansion, positioning Hong Kong as a gateway to Southeast Asian markets serving nearly 240 million diabetes patients. - The drug was previously approved in China in September 2022 and added to the National Reimbursement Drug List in January 2024.
- Virtuoso Surgical's robotic system received FDA Breakthrough Device Designation for bladder lesion removal via en bloc excision, positioning the company at the forefront of innovative bladder cancer care. - The system utilizes needle-sized robotic arms to enhance precision in minimally invasive endoscopic surgery, addressing significant clinical needs for improved specimen quality and cancer staging. - Recent randomized studies show manually performed en bloc techniques can lower one-year cancer recurrence rates versus standard TURBT, with Virtuoso aiming to enable widespread adoption through robotic assistance. - The FDA designation accelerates development and review processes, highlighting the system's potential to address critical gaps in bladder lesion removal compared to current endoscopic approaches.
- Immuno Cure and PharmaJet signed a collaboration agreement to evaluate the HIV therapeutic DNA vaccine ICVAX using PharmaJet's needle-free Tropis intradermal delivery system in clinical trials. - The partnership builds on ICVAX's successful Phase I trial results showing exceptional safety and promising immunogenicity profiles for achieving HIV virological control without antiretroviral therapy. - The study will be conducted at Prince of Wales Hospital in Hong Kong and leverages intradermal delivery to potentially enhance immune responses through the rich network of immune cells in the dermal layer. - This collaboration represents a significant step toward developing a functional cure for HIV/AIDS, addressing the critical need for effective immunotherapy beyond current antiretroviral treatments.
- Cornerstone Robotics raised over $70 million in Series C funding led by EQT to accelerate commercialization of its Sentire endoscopic surgical system and challenge established players like da Vinci. - The Hong Kong-based company received NMPA approval in China for its Sentire system in September 2024 and has successfully completed clinical trials across multiple surgical specialties including urology, general surgery, gynecology, and thoracic procedures. - Cornerstone's strategy of domestic component sourcing and vertical supply chain integration enables the company to offer performance equivalent to state-of-the-art systems at substantially lower prices than competitors. - The funding will support global expansion into Europe and Southeast Asia, development of new surgical robotics products, and advancement of international regulatory certifications.
